Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) and Senator Maggie Hassan (D-N.H.) have reintroduced the Stop Importation and Manufacturing of Synthetic Analogues (SIMSA) Act. The bipartisan legislation is aimed at addressing synthetic drugs that closely resemble controlled substances but are designed to avoid detection under current U.S. law.
Grassley stated, “America’s scheduling system is inefficient and outdated, and our law enforcement officers are struggling to keep pace with emerging drug threats. The SIMSA Act would provide much-needed adaptability to get ahead of bad actors and their deadly knockoffs.”
Hassan added, “Communities across New Hampshire have been devastated by fentanyl and other deadly drugs. Fentanyl analogues pose just as severe a threat as fentanyl itself, and criminals have deliberately engineered these drugs to circumvent our laws and evade bans. Our bipartisan legislation will provide law enforcement with the necessary tools to crack down on the criminals flooding our streets with these drug analogues. I urge my colleagues to support this effort to protect our communities and save lives, and I will keep working to combat the fentanyl crisis.”
The SIMSA Act proposes the creation of a new category called Schedule A for drugs whose chemical structure is substantially similar to an already controlled substance and which are expected to have equal or greater effects on the human body. The bill introduces criminal penalties for those manufacturing, exporting, or importing these substances while including measures that allow legitimate research to continue.
Current U.S. law prohibits unauthorized use of certain controlled substances, but drug manufacturers often alter molecular structures slightly in order to create new versions that are not yet regulated but can produce similar effects. This process currently requires lengthy analysis before authorities like the Drug Enforcement Administration can permanently classify them as illegal.
